Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.59 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.57 |
| ▸ | RIOK2 | Q9BVS4 | 5/20 | 0.56 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.56 |
| ▸ | GSK3A | P49840 | 3/20 | 0.56 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.56 |
| ▸ | HIPK1 | Q86Z02 | 1/20 | 0.56 |
| ▸ | SNRK | Q9NRH2 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.50 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24195991 | 0.85 | MEN1 (0.62) | L3MBTL1MEN1KMT2ANR1H4NLRP3 | |
| SCHEMBL28372186 | 0.84 | MEN1 (0.65) | L3MBTL1MEN1KMT2ANR1H4NLRP3 | |
| SCHEMBL1520280 | 0.84 | MEN1 (0.65) | L3MBTL1MEN1KMT2ANR1H4NLRP3 | |
| SCHEMBL6172461 | 0.83 | HDAC1 (0.57) | — | |
| SCHEMBL31189138 | 0.82 | MEN1 (0.59) | L3MBTL1MEN1KMT2ANR1H4NLRP3 | |
| SCHEMBL2038480 | 0.81 | L3MBTL1 (0.76) | L3MBTL1MEN1KMT2ANR1H4NLRP3 | |
| SCHEMBL11271316 | 0.80 | KMT2A (0.55) | MEN1KMT2ARIOK2MAPK10GSK3A | |
| SCHEMBL19851537 | 0.80 | HDAC8 (0.53) | L3MBTL1MEN1KMT2A | |
| SCHEMBL265881 | 0.79 | L3MBTL1 (0.56) | L3MBTL1MEN1KMT2ANR1H4NLRP3 | |
| SCHEMBL9367263 | 0.79 | NR1H4 (0.83) | L3MBTL1MEN1KMT2ANR1H4NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017481-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2018-07-10 | — | — | US | disclosed |
| US-10017481-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2018-07-10 | — | — | US | disclosed |
| US-9695191-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2017-07-04 | — | — | US | disclosed |
| EP-2499148-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2017-01-18 | — | — | EP | disclosed |
| US-20150051183-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2015-02-19 | — | — | US | disclosed |
| US-20150051183-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2015-02-19 | — | — | US | disclosed |
| US-20120270881-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2012-10-25 | — | — | US | disclosed |
| US-20120202821-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2012-08-09 | — | — | US | disclosed |
| US-7026326-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2006-04-11 | — | — | US | disclosed |
| US-20050038010-A1 | Substituted heterocyclic compounds and methods of use | AMGEN, INC. | 2005-02-17 | — | — | US | disclosed |
| EP-1506186-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003099808-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202821-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | HTR2B, MC1R, HTR1A | L3MBTL1 3373/4885MEN1 332/4885KMT2A 4240/4885 |
| US-10017481-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | CTSE, CTSB, CTSS | L3MBTL1 1546/4885MEN1 1674/4885KMT2A 4608/4885 |
| US-20050038010-A1 | Substituted heterocyclic compounds and methods of use | MYLK2, MYLK, MCL1 | L3MBTL1 319/4885MEN1 244/4885KMT2A 2833/4885 |
| US-20120270881-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | KCNB1, KCNAB1, KCNMB1 | L3MBTL1 4272/4885MEN1 559/4885KMT2A 3178/4885 |
| US-20150051183-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | CTSE, CTSB, CTSS | L3MBTL1 1546/4885MEN1 1674/4885KMT2A 4608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.